Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback
Tenax Therapeutics announced Phase 3 LEVEL trial results for TNX-103, missing primary endpoints while showing subgroup benefits.
Tenax's heart medicine didn't work as well as hoped in its big test, though it helped some patients. When a company's medicine doesn't meet its main goals, people watch carefully to see if the company can fix it or try something new.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.